Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Bullboard Posts
Comment by elgin1on Jan 09, 2019 2:13pm
69 Views
Post# 29207636

RE:RE:RE:RE:RE:First Patient Selected

RE:RE:RE:RE:RE:First Patient Selected
BioTeck wrote: Wow, you are a total moron. How am I putting anything down other than managements ability to deliver on time. You should spend more time learning about your investment instead of name calling. It is safe based on the last human trial. If you actually read the results you'd also know it wasn't "efficaous" (I'm assuming you meant efficacious). If it was, why would they be doing the same trial again? They think Shapiro botched the job and now they want someone else to do the same trial over again. Only thing that is going to raise the price is a deal or positive results in 2020. Till then, get used to .18-25 cents.


Bioteck, I have a medical background much more extensive than yours.   First of all Sernova never really officially released the results from Shapiros trial. He did it himself in a manner to muddy the results. Also if you go to Sernova;s webpage there are slides that show insulin producing cells and capillary growth.....   Shapiro just dumped a bunch of pancreatic tissue into the pouch. He had pancreatic enzymes, other tissues in the pouch .... unlike the present study whereby using purified islet cells. Did you see the sloppy job of surgery shapiro did? It looks like a great white shark bit the half the body of the patient.

Why would they do the same trail again?  Shapiro's protocols , methods, and parameters to measure statistically significant levels of insulin were non existent. Poor study by an amateur who was looking out to make a name for himeself.  Since the Pharma market is in the states predominantly, FDA approval is the gold standard for any new medical device or drug approval.
Your arguements are pathetic and personal.    Any other questions?
Bullboard Posts